SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Stock Valuation After Pioneering Gastric Cancer Approval
Regulatory catalyst for Shanghai Henlius Biotech stock
Shanghai Henlius Biotech (SEHK:2696) is in focus after China’s National Medical Products Administration approved a new indication for its anti PD 1 therapy HANSIZHUANG in resectable gastric cancer.
The approval is built on positive phase 3 data showing better event free survival and safety versus standard chemotherapy. It also marks the first immune monotherapy regimen to replace adjuvant chemotherapy for gastric cancer in the...